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Abstract
In cancer, combinations of drugs targeting different cellular functions is well accepted to improve tumor control. We
studied the effects of a Pseudomonas exotoxin A (PE) - based immunotoxin, the 9.2.27PE, and the BH-3 mimetic compound
ABT-737 in a panel of melanoma cell lines. The drug combination resulted in synergistic cytotoxicity, and the cell death
observed was associated with apoptosis, as activation of caspase-3, inactivation of Poly (ADP-ribose) polymerase (PARP) and
increased DNA fragmentation could be prevented by pre-treatment with caspase and cathepsin inhibitors. We further show
that ABT-737 caused endoplasmic reticulum (ER) stress with increased GRP78 and phosphorylated eIF2a protein levels.
Moreover, treatment with ABT-737 increased the intracellular calcium levels, an effect which was enhanced by 9.2.27PE,
which as a single entity drug had minimal effect on calcium release from the ER. In addition, silencing of Mcl-1 by short
hairpin RNA (shRNA) enhanced the intracellular calcium levels and cytotoxicity caused by ABT-737. Notably, the
combination of 9.2.27PE and ABT-737 caused growth delay in a human melanoma xenograft mice model, supporting
further investigations of this particular drug combination.
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Introduction
Surgical treatment of primary melanoma is associated with high
curative rate. However, if the melanoma has progressed to distant
metastases, treatment failure is common due to high resistance to
current treatment modalities [1,2]. The median survival rate of
metastatic melanoma is 6 months, and less than 5% of the patients
survive 5 years, making metastatic melanoma one of the most
aggressive cancers in humans [1]. The mitogen-activated protein
kinase (MAPK) pathway is constitutively activated in approxi-
mately 90% of all melanomas [3], and new drugs targeting this
pathway, e.g inhibitors of mutated BRAF or MEK, initially
showed promising effects in vitro. PLX4032, a selective BRAF
V600E
inhibitor, caused partial or complete response in early clinical trials
[4,5], however the patients eventually develop resistance. The
MEK inhibitors PD0325901 and AZD6244 have also been
evaluated in early clinical trials, however, without improvement
in the progression-free survival compared to Temozolomide [6],
an oral form of the chemotherapeutic drug Dacarbazine used to
treat melanoma patients. These results underscore the importance
of developing new drugs with yet different mechanisms of action.
An immunotoxin (IT) consists of an antibody linked to a toxin
and is designed to specifically kill tumor cells, as the antibody
targets cancer cell-associated antigens or antigens over expressed
on cancer cells. ITs are taken up through endocytosis, processed
within the cell, and cell death is caused by inhibition of protein
synthesis through ADP-ribosylation of Elongation Factor 2 and by
induction of apoptosis [7]. The 9.2.27PE immunotoxin consists of
the Pseudomonas Exotoxin A (PE) linked to the 9.2.27 antibody
that targets the high molecular weight-melanoma associated
antigen, an antigen expressed on most melanomas and melanoma
cell lines [8,9]. Previous studies show that other PE-based
immunotoxins cause strong induction of apoptosis [7,10]. The
9.2.27PE, on the other hand, caused cell death in melanoma cells
primarily through inhibition of protein synthesis, with minor signs
of apoptosis [11]. This is possibly due to the high resistance to
apoptosis in melanoma cells [2]. Apoptosis is commonly associated
with activation of caspases, inactivation of the DNA repair enzyme
PARP, chromatin condensation and fragmentation of DNA. It
involves two major pathways, the intrinsic/mitochondrial and
extrinsic/death receptor apoptotic pathway, which interlace at
certain points and ultimately result in cell death [12]. Further-
more, complex interplay between the pro- and anti-apoptotic
members of the Bcl-2 family proteins ensures the homeostatic
balance within the cell. The Bcl-2 family proteins have an
important role in regulating the intrinsic apoptotic pathway, but
have also been shown to be involved in maintaining the
endoplasmic reticulum (ER) homeostasis, as well as being involved
in ER stress signal transduction pathways [13].
The small-molecule inhibitor ABT-737 is developed to neutralize
the pro-survival effects of Bcl-2 family proteins. It binds to and
inhibits the pro-survival proteins Bcl-2, Bcl-XL and Bcl-W, but not
Mcl-1 and A1 [14]. By binding to Bcl-2 and Bcl-XL, pro-apoptotic
proteins such as BAX and BAK may be released from Bcl-2 and
Bcl-XL and subsequently induce apoptosis as they are proteins of
the intrinsic apoptotic pathway. Others have shown that combining
ABT-737 with agents decreasing Mcl-1 protein expression act
synergistically with ABT-737 [15,16], and depletion of Mcl-1
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Lymphoblastic Leukemia cells, indicating that elevated Mcl-1
expression is important for Fbw7-deficient cells to evade apoptosis
[17]. We have previously shown that by treating melanoma cells
with9.2.27PE, the Mcl-1 protein level is rapidly decreased due to its
short half-life [11]. We therefore hypothesized that by combining
9.2.27PE and ABT-737, synergistic cell cytotoxicity could be
achieved in melanoma cells with high apoptotic resistance.
We have assessed the effect of combining the 9.2.27PE
immunotoxin with the BH-3 mimetic ABT-737 in a panel of
melanoma cells. The results suggest that the combination
treatment causes strong synergistic cytotoxic effects. Importantly,
the combination of the two drugs caused a cytostatic effect on the
growth of human melanoma xenograft in mice.
Materials and Methods
Immunotoxins and reagents
The immunotoxins 9.2.27PE and 425.3PE, the mAb 9.2.27 and
the toxin Pseudomonas Exotoxin A (PE) have previously been
described [11]. The agents were diluted in PBS 0.1% human
serum albumin (Octapharma, Stockholm, Sweden). Control cells
were given 0.1% human serum albumin. ABT-737 and its
enantiomer A-793844 (kindly provided by Abbott Laboratories,
Abbott Park, IL), were dissolved in DMSO (Sigma-Aldrich, St.
Louise, MO), and stored at 220uC until used. For the in vivo
studies, ABT-737 was dissolved as previously described [18]. The
pan-caspase inhibitor Z-VAD-FMK, the cathepsin B/L inhibitor
Z-FA-FMK and the caspase-3 inhibitor Z-DEVD-FMK were
from Calbiochem (La Jolla, CA). Cycloheximide (CHX) and
Staurosporine (STS) were from Sigma-Aldrich, and Tunicamycin
was from Sigma Chemical (Castle Hill, Australia). Control cells
were given dimethyl sulfoxide (DMSO) (Sigma-Aldrich).
Antibodies
The following antibodies were used; anti-a-tubulin (Calbio-
chem, La Jolla, CA), anti-GAPDH (Applied Biosystems, Mulgrave,
Australia), anti-PARP (Calbiochem and BD Bioscience, San Jose,
CA), anti-caspase-3 (R&D Systems, Minneapolis, MN), anti-BAX,
anti-peIF2a, anti-eIF2a (Cell Signaling Technology, La Jolla, CA),
anti-Mcl-1, anti-GRP78/BiP and anti-CHOP/GADD 153 (Santa
Cruz Biotechnology, Santa Cruz, CA).
Cell culture
The FEMX, Melmet-1, Melmet-5 and Melmet-44, previously
described [19,20], were kept in RPMI-1640 medium supplemented
with 8% heat inactivated fetal calf serum, Hepes and Glutamax
(Gibco, Paisley, UK) at 37uC. The MM200 and MelRM (kindly
provided by P. Hersey, Calvary Mater Newcastle Hospital,
Australia, [21,22]), were kept in DMEM (Sigma-Aldrich, Castle
Hill, Australia) supplemented with 5% fetal calf serum (Sigma-
Aldrich), supplemented with 2 mg/ml Sodium Bicarbonate (Chem-
Supply, Thermo Scientific, Scoresby, Australia), 20 mg/ml Genta-
micin (Pfizer Australia, West Ryde, Australia) at 37uC (100%
humidity, 5% CO2, 95% air). For all in vitro experiments, cells were
seededonedaypriorto startoftheexperiments,andthecellswerein
growth phase and never below 60% confluent at start of treatment.
The cells were treated with 100 ng/ml 9.2.27PE or 10 mM ABT-
737, unless otherwise indicated. All cell lines were routinely tested
and found to be free from contamination with Mycoplasma species.
Transduction with short hairpin RNA
Mcl-1 were silenced in MelRM cells (MelRMshMcl-1) by
transduction using short hairpin RNA (clone ID NM_021960.3-
664s1c1, Sigma-Aldrich) according to manufacturer’s instructions.
Control cells (MelRMshCtr) were generated using non-target
control sequence (Product no. SH002, Sigma-Aldrich). The
expression level of Mcl-1 was determined by Western Blot.
Cell viability assay
Cell viability of the FEMX, Melmet-1, Melmet-5, Melmet-44,
MelRM and MM200 after treatment for 24 or 48 h with 9.2.27PE
(1–1000 ng/ml), ABT-737 (0.1–20 mM) or a combination of
9.2.27PE and ABT-737 was measured using CellTiter 96HAQueous
One Solution Cell Proliferation Assay (MTS assay; Promega,
Madison, WI) as described previously [11] or the VisionBlue
TM
Quick Cell Viability Assay (BioVision, Mountain View, CA). We
rule out that there was a difference between the two cell viability
assays, as the cell viability results of FEMX cells treated with
9.2.27PE and ABT-737 were similar using the two different
agents. For this cell line, data from both the methods/agents were
used to calculate the cell viability results. Cell viability of
9.2.27PE6ABT-737 treated MelRM, MelRMshCtr and
MelRMshMcl-1 (12 and 24 h) was determined in a separate
experiment.
To determine whether caspases and cathepsins were involved in
the decreased cell viability observed, FEMX cells were pre-treated
for 45–60 min with Z-VAD-FMK (50 mM)6Z-FA-FMK (50 mM)
prior to treatment with 9.2.27PE6ABT-737. Assays were
performed in triplicate and repeated at least three times.
Furthermore, FEMX and MelRM cells were treated with A-
793844, the enantiomer of ABT-737, with concentrations up to
10 mM for 24 and 48 h (48 h: FEMX cells only). Assays were
performed in triplicate and repeated three times.
Caspase activity assay
The activity of caspase-3/7 in FEMX and Melmet-5 cells were
measured using the Caspase-Glo 3/7 (Promega, Madison, WI)
as described previously [20]. The cells were pre-treated for
45 min with Z-DEVD-FMK (50 mM) prior to treatment with
9.2.27PE6ABT-737, STS (1 mM) or CHX (10 mg/ml). The
activity was measured after 24 h according to the manufacturer’s
instructions. Assays were performed in triplicate and repeated
three times.
Mitochondrial Membrane Potential
The mitochondrial membrane potential (Dym)i n
9.2.27PE6ABT-737 treated FEMX and Melmet-5 cells using the
MitoProbe
TM JC-1 Assay Kit (Molecular Probes, Eugene, OR) was
performed as described previously [11]. In addition FEMX,
Melmet-5 and MelRM were treated with ABT-737 for 24, 32
and 48 h. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) at a
final concentration of 50 mM was used as depolarization control.
The experiments were repeated three times. MelRM, MelRMshCtr
and MelRMshMcl-1 cells were also treated with 9.2.27PE+ABT-
737 for 12 h. This experiment was repeated 3 times.
Western Blot Analysis
FEMX, Melmet-5 and MelRM cells were treated as indicated in
the figures and subjected to Western Blot analysis as previously
described [11]. Equal amounts of protein (20 mg) were separated
by NuPAGE Bis-Tris (Invitrogen, Carlsbad, CA) or SDS-PAGE
gels, transferred by electrophoresis to Immobilon membrane
(Millipore, Bedford, MA), and probed as previously described
[11]. When necessary, the membranes were stripped using
Restore
TM Western Blot Stripping Buffer (Thermo Scientific
Pierce Protein Research Products, Rockford, IL) and re-probed
with the desired primary antibody.
9.2.27PE and ABT-737 in Melanoma
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TUNEL analysis was performed to determine DNA fragmen-
tation in FEMX and Melmet-5 cells as previously described [11].
The Melmet-5 cells were pre-treated with Z-VAD-FMK
(50 mM)+Z-FA-FMK (50 mM) for 45 min. FEMX and Melmet-5
cells were subsequently treated with 9.2.27PE6ABT-737 for 24 h.
The experiments were repeated at least three times.
Quantitation of dead cells by measurement of sub-G1 DNA
content using propidium iodide assay was carried out. FEMX,
Melmet-5 and MelRM cells were treated with ABT-737 for 24, 32
and 48 h, harvested, washed with PBS, fixed in icecold MeOH
and kept at 220uC until analysis. The cells were washed twice in
PBS before subjected to PI (5 mg/ml) and RNase and analyzed on
a BDFACSCanto
TM (Becton Dickinson, San Jose, CA). The
experiment was repeated at least twice for each time point.
Intracellular calcium levels
FEMX, Melmet-5, MelRM, MelRMshCtr and MelRMshMcl-1
cells were treated with 9.2.27PE6ABT-737 for 12, 16 or 24 h.
Cells were collected, washed with PBS, incubated with 1 mM
Calcium Green
TM-1 (Molecular Probes) for 30 min, washed with
PBS and subjected to flow cytometric analysis on a Becton
Dickinson FACSCanto
TM (Becton Dickinson). Intact cells were
gated in a forward and side scatter analysis, and results are
reported in median fluorescence intensity of the intact cells.
Untreated cells were set to the given value 1, and values for the
treated cells were calculated accordingly. The experiment was
repeated at least three times for each time point per cell line.
Analysis was carried out on ,10.000 cells per sample.
Ethics Statements
All procedures and experiments involving animals were
approved by The National Animal Research Authority and
carried out according to the European Convention for the
Protection of Vertebrates used for Scientific Purposes. Nude
female mice (BALB/c (nu/nu)) were bred in our nude rodent
facility. The animals were kept in a specific pathogen-free
environment, in positive pressure rooms with filtered and
humidified air. The animals were kept under standard conditions,
and food and water were supplied ad libitum.
In vivo studies
Nude female mice with Melmet-5 xenografts in the right and
left flanks were used. Tumors were size-matched with an average
volume of 150–161 mm
3/group. The animals were divided into
four groups; control, 9.2.27PE, ABT-737 and 9.2.27PE+ABT-737.
Treatment was initiated with 10–12 tumors per group and mean
body weight #31 g. ABT-737 (100 mg/kg) was administered once
daily on day 1–5 and 15–19 by intraperitoneal injection. The
9.2.27PE immunotoxin (31.25 mg/kg) was given intravenously 5–
6 h after ABT-737 treatment on day 1 and 15. All animals
administered ABT-737 developed skin rash, no other adverse
effects were observed. Two animals in the 9.2.27PE6ABT-737
group developed skin ulcers and were sacrificed on day 8 and 21.
For the second experiment, the concentration of ABT-737 was
decreased to 50 mg/kg and administered on day 1–5 and 15–19.
The 9.2.27PE immunotoxin (31.25 mg/kg) was given 5–6 h after
ABT-737 treatment on day 1 and 15. Treatment commenced
when the mean tumor volume reached 92–102 mm
3/group and
the mean body weight #31 g. For unknown reasons, two mice
died shortly after treatment start in the combination group, and
were not included in the final analysis. One mice died for
unknown reasons on day 15, no other adverse events were
recorded. Tumor size was measured 1–3 times weakly by caliper
measurements and tumor volume was calculated (tumor volu-
me=L6W
2/2). Tumor volume was plotted against time (days).
Body weight was recorded throughout the experiments. ANOVA
was used to calculate statistical differences between groups. Results
with a p value less than 0.05 were regarded as significant.
Results
9.2.27PE and ABT-737 reduced cell viability in a panel of
melanoma cells
The 9.2.27PE induced a time- and dose dependent decrease in
cell viability in the FEMX, Melmet-1, Melmet-5, Melmet-44,
MelRM and MM200 cells (Fig. 1A). The effect of 9.2.27PE was
consistent in the five cell lines, as opposed to the effect of ABT-
737. ABT-737 IC50 was obtained in MelRM and MM200 after
24 h (Fig. 1B and C). With increased exposure time to 48 h, IC50
was also obtained in FEMX and Melmet-1 cells. Melmet-5 and
Melmet-44 cell proved to be less sensitive to ABT-737 with
IC50.20 mM after 48 h treatment. The sensitivity of the cells to
9.2.27PE or ABT-737 was not related to the BRAF status of these
cell lines (Fig. 1C). Furthermore, 24 h treatment with the 425.3PE
immunotoxin (100 ng/ml) targeting the epidermal growth factor
receptor (EGFR), the antibody 9.2.27 (100 ng/ml) or the PE
(100 ng/ml) did not result in decreased cell viability in MelRM
cells (data not shown). These results are consistent with results
previously obtained for the FEMX cells, emphasizing the
specificity of the 9.2.27PE immunotoxin [11].
9.2.27PE in combination with ABT-737 synergistically
induce apoptosis
To investigate whether the combination of 9.2.27PE and
ABT-737 could induce synergistic cytotoxicity in melanoma cells,
the cells lines were exposed to different concentrations of the
two drugs for 24 and 48 h. The CalcuSyn software program
was used to calculate synergistic, additive or antagonistic effects.
Combining 10 ng/ml 9.2.27PE+1 mM ABT-737 or 100 ng/ml
9.2.27PE+10 mM ABT-737 caused combination index (CI) values
in the 0.59 to 0.003 range, indicating synergy to very strong
synergy, after 24–48 h (Fig. 1D and Table S1) [23].
As seen in Figure 2A, 9.2.27PE+ABT-737 caused clear
cytotoxic effect in both FEMX and Melmet-5 cells, with
morphologically rounding of the cells and detachment from the
surface of the flasks, compared to single agent treatments with
9.2.27PE or ABT-737, where only a few cells had started to round
up. Similar effects were seen in MelRM cells (data not shown). As
both FEMX and MelRM cells proved to be sensitive to the ABT-
737 (Fig. 1B), they were further treated with A-793844, the
enantiomer and negative control of ABT-737. With concentra-
tions up to 10 mM, no decrease in cell viability was observed after
24 h or 48 h (48 h: FEMX cells only) (Figure S1).
The cytotoxic effect observed when combining 9.2.27PE and
ABT-737 was associated with apoptosis, as enhanced PARP
inactivation and activation of caspase-3 was observed in both
FEMX cells and Melmet-5 cells after 24 h treatment (Fig. 2B and
C). Pre-treatment of the Melmet-5 cells with the pan-caspase
inhibitor Z-VAD-FMK or the cathepsin B/L inhibitor Z-FA-
FMK resulted in a shift upwards of the caspase-3 band from p17 to
p19, indicating that the active caspase-3 was blocked (Fig. 2C)
[24]. In addition to inhibiting the inactivation of PARP, the
combination of the two inhibitors suppressed the processing of the
procaspase-3 protein. Furthermore, pre-treatment of the FEMX
cells with the combination of Z-VAD-FMK and Z-FA-FMK,
inhibited the synergistic cytotoxic effect caused by 9.2.27PE
9.2.27PE and ABT-737 in Melanoma
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737 (1 mM) in FEMX cells (Fig. 2D and data not shown),
combinations which caused synergistic cytotoxic effects (Fig. 1D).
A caspase-3/7 activity assay was utilized to confirm activity of
the cleaved caspase-3 band detected on Western Blot. As seen in
Figure S2, 9.2.27PE6ABT-737 increased caspase-3/7 activity
after 24 h in both the FEMX and the Melmet-5 cells. The caspase-
3/7 acticity was effectively blocked by pre-treatment with the
caspase-3 II inhibitor (Z-DEVD-FMK, 50 mM). STS (1 mM),
which we previously have shown to induce caspase-3/7 activity in
FEMX cells [11], was used as a positive control, and CHX, not
causing caspase-3/7 activity [25], was used as a negative control.
9.2.27PE in combination with ABT-737 cause strong
depolarization of the mitochondrial membrane
Decreased Dym is linked to apoptosis as pro-apoptotic proteins,
which are released from the mitochondria into the cytosol, are
capable of activating caspase-3 and inducing DNA fragmentation.
We used the cation dye JC-1 to detect whether the Dym was
affected by 9.2.27PE6ABT-737 in FEMX and Melmet-5 cells.
JC-1 fluoresces red in intact mitochondria, and upon collapse of
the membrane, JC-1 accumulates in the cytoplasm where it
fluoresces green. A decrease in red/green ratio indicates
depolarization of the mitochondrial membrane. In FEMX cells,
the red/green ratio decreased from 0.62 and 0.52 for the 9.2.27PE
and ABT-737 treatments, respectively, to 0.22 for the combination
treatment (Fig. 3A). Similar results were obtained for the Melmet-5
cells, where the red/green ratio decreased from 0.77 and 0.90 for
the 9.2.27PE and ABT-737 treatments, respectively, to 0.15 for
the 9.2.27PE+ABT-737 combination. CCCP was used as a
positive control for depolarization.
We next analysed DNA fragmentation by TUNEL assay. As
seen in Figure 3B, 24 h treatment with 9.2.27PE and ABT-737
caused DNA fragmentation in ,20% and 5% of the Melmet-5
cells, respectively. Combining the two drugs, the percentage of
DNA fragmentation increased to ,60%. Pre-incubation with Z-
VAD-FMK+Z-FA-FMK inhibited the DNA fragmentation, indi-
cating that caspases and cathepsins are involved in the cell death
process. For the combination treatment, the caspase-3/7 activa-
tion in Melmet-5 cells (Figure S2) did not directly correlate with
the strong increase in DNA fragmentation (Fig. 3B) suggesting that
other factors than caspase-3/7 might be involved in DNA
fragmentation [26]. In a previous study with 9.2.27PE treated
FEMX cells, no DNA fragmentation was detected using the
TUNEL assay [11]. In the present study, no DNA fragmentation
was detected in FEMX cells treated with 9.2.27PE6ABT-737
(Fig. 3B). As the combination treatment caused strong depolar-
ization of the mitochondrial membrane in addition to caspase-3
activity, we conclude that under the above mentioned conditions,
and after treatment with STS [11], DNA fragmentation does not
take place in the FEMX cells.
ABT-737 induces ER stress and cell death
We wanted to investigate which mechanisms could contribute to
the synergistic cell death effect observed by the 9.2.27PE+ABT-737
combination treatment. As prolonged ER stress can lead to
apoptosis and autophagy [13], we first investigated whether ABT-
737 was able to induce ER stress in melanoma cells. The commonly
used markers for ER stress, GRP78 and peIF2a, were increased in
the ABT-737 treated FEMX, Melmet-5 and MelRM cells (Fig. 4A),
the increase was more pronounced in the Melmet-5 and MelRM
cells. Treatment with 9.2.27PE did not induce increased protein
levels of GRP78, however an increase in peIF2a was observed.
Tunicamycin, which is known to induce ER stress, was used as a
positive control for increased GRP78. During ER stress, GRP78
dissociates fromthethree ER membrane proteins PERK, IRE1 and
ATF6. This process leads to activation of these proteins,
transcriptional activation of CHOP and may result in apoptosis
[27]. CHOP was induced upon 9.2.27PE treatment, but interest-
ingly notupon ABT-737treatmentinFEMX,Melmet-5orMelRM
cells despite increased levels of GRP78 and peIF2a. Further
investigations are needed to clarify the involvement of CHOP in
9.2.27PE and ABT-737 treated melanoma cells. Nevertheless,
ABT-737 treatment caused decreased Dym (Fig. 4B), inactivation of
PARP (Fig. 4A) and increased sub-G1 fraction (Fig. 4C), after 48 h
in FEMX, Melmet-5 and MelRM cells. These results indicate that
ABT-737 was able to induce ER stress and cell death in melanoma
cells in vitro.
9.2.27PE enhances Ca
2+ efflux from Endoplasmic
reticulum induced by ABT-737
One function of the ER is storage and regulation of calcium.
We therefore investigated whether 9.2.27PE6ABT-737 caused
calcium release from the ER in melanoma cells. ABT-737 caused
an increase in intracellular calcium ([Ca
2+]i) levels in FEMX,
Melmet-5 and MelRM cells after 16 and 24 h (Fig. 5A). The
increased [Ca
2+]i levels was most pronounced in FEMX cells.
The 9.2.27PE, which as a single agent had minor effect on
calcium release, enhanced the [Ca
2+]i levels caused by ABT-737.
The enantiomer A-793844 was not able to elicit increased [Ca
2+]i
levels in Melmet-5 or MelRM cells after 16 and 24 h (data not
shown). FEMX cells were not tested with the A-723844 for this
purpose.
In contrast to the control cells (MelRM and MelRMshCtr),
silencing of Mcl-1 in the MelRM (MelRMshMcl-1) lead to
significantly increased [Ca
2+]i levels, decreased Dym and de-
creased cell viability after 12 h ABT-737 treatment, effects which
could not be further enhanced by 9.2.27PE (Fig. 5B). As the Mcl-1
level after 12 h 9.2.27PE treatment was undetectable (Fig. 5B) in
all three cell lines, these results indicate that silencing of Mcl-1
through shRNA or 9.2.27PE treatment is responsible for the
increased [Ca
2+]i levels during ABT-737 treatment. The control
cells, MelRM and MelRMshCtr, showed only a significant
increase in [Ca
2+]i levels when treated with 9.2.27PE+ABT-737,
ant not with ABT-737 as a single agent treatment. The 9.2.27PE
had no effect on calcium release in either of the MelRM cell lines
after 12 h. Interestingly, 9.2.27PE caused less decrease of cell
viability in MelRMshMcl-1 cells compared to control cells after
12 h (Fig. 5B) and 24 h (Figure S3), indicating a role of Mcl-1 in
mediating the cytotoxicity of 9.2.27PE.
Figure 1. 9.2.27PE in combination with ABT-737 causes synergistic cell cytotoxicity in melanoma cells. (A) The 9.2.27PE immunotoxin
caused a time- and dose dependent decrease of cell viability in melanoma cells. The effect of the immunotoxin was similar in the different cell lines
tested. MM200: 24 h experiment only. (B) ABT-737 caused decreased cell viability in a panel of melanoma cells. The cell cytotoxic effect of ABT-737
differed between the cell lines. (C) B-RAF status and IC50 values of ABT-737 treated melanoma cells. WT=wild type, M=BRAF
V600E, UNK=unknown.
(D) The CalcuSyn software program was used to calculate synergistic, additive or antagonistic effects. Combining 10 ng/ml 9.2.27PE+1 mM ABT-737 or
100 ng/ml 9.2.27PE+10 mM ABT-737 caused combination index (CI) values in the 0.59 to 0.003 range indicating synergy to very strong synergy after
24–48 h.
doi:10.1371/journal.pone.0024012.g001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24012Figure 2. 9.2.27PE in combination with ABT-737 induces apoptosis in melanoma cells. (A) FEMX cells and Melmet-5 cells were treated with
9.2.27PE (100 ng/ml)6ABT-737 (10 mM) for 24 h. The combination treatment caused rounding of the cells and detachment from the surface of the
flasks as compared to single agent treatment. (B) FEMX cells were treated with various doses of 9.2.27PE (1–100 ng/ml) or various concentrations of
ABT-737 (0.1–10 mM) or a combination of 9.2.27PE (100 ng/ml) and ABT-737 (10 mM) for 24 h. Cells were subjected to Western Blot analysis for
examination of the levels of PARP, Mcl-1, Caspase-3, BAX and a-tubulin. The blot is a representative of three individual experiments. (C) Melmet-5 cells
were treated with 9.2.27PE (100 ng/ml)6ABT-737 (10 mM) for 24 h. Cells were subjected to Western Blot analysis for examination of the levels of
PARP, Caspase-3, BAX and a-tubulin. To determine whether caspases and cathepsins were involved in the inactivation of PARP and activation of
caspase-3, the cells were pre-treated for 1 h with Z-VAD-FMK (50 mM)6Z-FA-FMK (50 mM) before treatment with 9.2.27PE+ABT-737. The blot is a
representative of three independent experiments. (D) Cell viability was measured in FEMX cells treated with 9.2.27PE (100 ng/ml)6ABT-737 (10 mM)
for 24 h. To determine whether caspases and cathepsins were involved in the decreased cell viability caused by the combination of 9.2.27PE and ABT-
737, the cells were pre-treated with for 1 h with Z-VAD-FMK (50 mM)6Z-FA-FMK (50 mM). The data represents the mean 6 SD.
doi:10.1371/journal.pone.0024012.g002
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Our in vitro data demonstrated that a combination of 9.2.27PE
and ABT-737 caused synergistic cytotoxic effects in a panel of
melanoma cells. To determine whether these effects could be
validated in vivo, nude mice with subcutaneous Melmet-5
xenografts were treated with 9.2.27PE and ABT-737. As seen in
Figure 6A, the combination regime of 9.2.27PE (31.25 mg/
kg)+ABT-737 (100 mg/kg) caused significant cytostatic effect after
21 and 25 d (p,0.05). As all animals receiving 100 mg/kg ABT-
737 developed skin rash, the concentration of ABT-737 was
halved in the second experiment (Fig. 6B). Skin rash was not
observed, but the combination treatment did not significantly
decrease inhibition of tumor growth, possibly due to large tumor
volume variations within the groups. There was, however, a
tendency to stronger cytostatic effect caused by the combination
treatment compared to treatment with ABT-737 or 9.2.27PE as
single agents. Body weight was stable throughout the experiments
(Figure S4).
Discussion
Cancer cells are characterized by uncontrolled proliferation and
apoptotic resistance. Melanoma cells are particularly drug
resistant, and drug-resistance is often correlated with apoptosis
evasion [2]. Drug resistance is likely a reason for treatment failure
Figure 3. 9.2.27PE in combination with ABT-737 induces strong depolarization of the mitochondrial membrane. (A) FEMX and
Melmet-5 cells were treated with 9.2.27PE (100 ng/ml)6ABT-737 (10 mM) for 24 h and subsequently stained with JC-1, an indicator for mitochondrial
membrane potential. A decrease in the red/green fluorescence ratio indicates decreased mitochondrial membrane potential. CCCP was used as a
depolarization control. The figures shown are examples from one representative experiment. The red/green ratio value is based on three
independent experiments. (B) DNA fragmentation was analyzed by TUNEL assay. FEMX and Melmet-5 cells were treated with 9.2.27PE (100 ng/
ml)6ABT-737 (10 mM) for 24 h. In addition, the Melmet-5 cells were pre-treated with for 1 h with Z-VAD-FMK (50 mM)6Z-FA-FMK (50 mM) to
determine whether caspases and cathepsins were involved in the DNA fragmentation observed in this cell line.
doi:10.1371/journal.pone.0024012.g003
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MelRM melanoma cells treated with ABT-737 (10 mM) up to 48 h, indicating ER stress. CHOP protein was only increased with 9.2.27PE treatment. Both
ABT-737 and 9.2.27PE caused inactivation of PARP, indicating apoptosis. GAPDH and amidoblack staining was used as a loading control. Tunicamycin
(3 mM), was used as a positive control for ER stress. The blot is representative of at least three independent experiments, except for the 32 and 48 h
time point where the experiments were repeated twice. Lane 1: Vehicle (DMSO), 2: ABT-737 1 h, 3: ABT-737 2 h, 4: ABT-737 4 h, 5: ABT-737 8 h, 6:
ABT-737 16 h, 7: ABT-737 24 h, 8: ABT-737 32 h 9: ABT-737 48 h, 10: Vehicle (PBS 0.1% human serum albumin), 11: 9.2.27PE 8 h, 12: 9.2.27PE 16 h, 13:
9.2.27PE 24 h, 14: Tunicamycin 8 h. (B) Mitochondrial membrane potential was measured using the JC-1 dye. A decrease in red/green ratio is
indicative of depolarization of the mitochondrial membrane. The data represents the mean 6 SD. (C) FEMX, Melmet-5 and MelRM cells were treated
with ABT-737 (10 mM) for 24–48 h before stained with propidium iodide for quantitation of dead cells. An increase in the percentage sub-G1
represents increased cell death compared to control cells. The data represents the mean 6 SD.
doi:10.1371/journal.pone.0024012.g004
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important and widely applicable target for anti-cancer immuno-
therapeutic strategies, and spontaneous cellular immune responses
against the Bcl-2 family proteins have been identified as frequent
features in cancer patients [28]. These observations underscore
that the Bcl-2 family proteins are natural targets for the immune
Figure 5. Calcium release caused by 9.2.27PE±ABT-737 in melanoma cells. (A) FEMX, Melmet-5 and MelRM cells were subjected to 9.2.27PE
(100 ng/ml)+ABT-737 (10 mM) for 16 and 24 h before subjected to flow cytometric analysis using Calcium Green
TM-1. The 9.2.27PE enhanced calcium
release caused by ABT-737. The data shown are the mean 6 SD for at least three independent experiments. (B) MelRM, MelRMshCtr and MelRMshMcl-
1 were subjected to 9.2.27PE (100 ng/ml)+ABT-737 (10 mM). [Ca
2+]i levels, mitochondrial membrane potential and cell viability was measured after
12 h. Knockdown of Mcl-1 using shRNA enhanced the calcium release and decreased cell viability caused by ABT-737, an effect which could not be
enhanced by 9.2.27PE. The data shown are the mean 6 SD. P12=passage 12, the highest passage used for this experiment.
doi:10.1371/journal.pone.0024012.g005
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anti-cancer immunotherapeutic strategies [28]. The combined use
of several drugs targeting different cellular functions, e.g. the Bcl-2
family, is therefore one approach to achieve tumor control in
cancer, including melanoma.
In the present study we show that the melanoma specific
immunotoxin 9.2.27PE in combination with the BH-3 mimetic
ABT-737, caused strong synergistic cytotoxic effect in the panel of
melanoma cells, independently of their BRAF status and, as
previously reported [20], their sensitivity to Dacarbazine.
Depolarisation of the mitochondrial membrane, activation of
caspase-3, inactivation of PARP and increased DNA fragmenta-
tion was obtained using the combination treatment, hence, cell
death involved induction of the intrinsic apoptotic pathway.
To elucidate which mechanisms are responsible for the
synergistic cytotoxic effect observed when treating melanoma cells
with 9.2.27PE+ABT-737, we looked to the ER, as ABT-737 has
been reported to induce the transcription factor ATF4 in other
types of cancer [29,30]. Disturbances in the normal functions of
the ER lead to unfolded protein response and ER stress [31]. The
initial intent of the unfolded protein response is to adapt to these
changes and re-establish normal ER function. This happens
through dissociation of GRP78 from the three ER chaperones
PERK, IRE1 and ATF6, resulting in increased protein levels of
GRP78 and activation of the three ER stress pathways (PERK–
eIF2a–ATF4, ATF6-ATF6 splicing, and IRE1-XBP1) [31,32].
Unresolved and prolonged ER stress will eventually result in
apoptosis [32]. In this study, ABT-737 treatment resulted in
increased protein levels of GRP78 and peIF2a, indicative of ER
stress. In addition, ABT-737 treatment resulted in decreased Dym,
inactivation of PARP and increased sub-G1 population, mecha-
nisms related to apoptosis. These results indicate that ABT-737 as
a single agent induces ER stress which ultimately results in cell
death.
Another function of the ER is storage and regulation of calcium.
Upon ER stress, calcium is released from the ER into the cytosol
which can be taken up by juxtaposed mitochondria and result in
decreased Dym [33]. In this study we show that ABT-737
increased [Ca
2+]i levels, and that 9.2.27PE, which as a single agent
had minimal effect on calcium release, enhanced the ABT-737
induced calcium release from ER. This result suggests that
9.2.27PE directly or indirectly has an effect on ER and is effective
for sensitizing the melanoma cells to ABT-737. Others have shown
that decreased Mcl-1 expression is effective for sensitizing cancer
cells to ABT-737 and induce apoptosis [15,16]. As 9.2.27PE lead
to rapid decrease in Mcl-1 protein levels [11], this lead us to
investigate whether knockdown of Mcl-1 protein expression could
increase the [Ca
2+]i levels, decrease the Dym and decrease the cell
viability in ABT-737 treated melanoma cells. In contrast to the
control cells (MelRM and MelRMshCtr), ABT-737 treated
MelRMshMcl-1 cells showed significantly increased [Ca
2+]i levels,
decreased Dym and decreased cell viability, effects which could
not be further enhanced by 9.2.27PE in the MelRMshMcl-1 cells.
These results indicate that Mcl-1 has an inhibitory effect on
calcium release from the ER, and that strongly decreased Mcl-1
protein levels in melanoma cells after treatment with 9.2.27PE
(Fig. 4A) might be responsible for enhanced [Ca
2+]i levels in ABT-
737 treated cells. Calcium release has been shown to take place
through the inositol 1,4,5-triphosphate receptor and the ryanodine
receptors in the ER membrane [13,31]. Bcl-2 family proteins are
involved in this process, as several members, including Mcl-1, have
been shown to interact with e.g. inositol 1,4,5-triphosphate
receptor [34–38]. The precise mechanisms how the
9.2.27PE+ABT-737 drug combination causes calcium release
and synergistic cell death in melanoma cells is under investigation.
The downstream effectors of increased [Ca
2+]i levels, are
numerous and thoroughly reviewed by Xu et al [31]. Of
importance to the present study is the mitochondrial uptake of
excessive Ca
2+ leading to decreased Dym, activation of the
intrinsic apoptotic pathway via release of a number of pro-
apoptotic factors including cytochrome c, apoptosis inducing factor
(AIF) and Smac/Diablo [39]. The enhanced [Ca
2+]i levels caused
by 9.2.27PE+ABT-737 treatment could therefore explain the
increased mitochondrial membrane depolarization caused by the
Figure 6. Effect of 9.2.27PE in combination with ABT-737 in a Melmet-5 xenograft model. (A) Nude mice were treated with ABT-737
(100 mg/kg) day 1–5 and 15–19 and 9.2.27PE (31.25 g/kg) on day 1 and 15. (B) Nude mice were treated with ABT-737 (50 mg/kg) day 1–5 and 15–19
and 9.2.27PE (31.25 g/kg) on day 1 and 15. Tumor size was measured 1–3 times weakly by caliper measurements and tumor volume was calculated
(tumor volume=L6W
2/2). * indicates p value,0.05, using ANOVA. Arrows indicate the day animals in the combination group were sacrificed due to
adverse events (skin ulcers).
doi:10.1371/journal.pone.0024012.g006
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effect that subsequently resulted in synergistic decrease in cell
viability and strong induction of apoptosis.
As ABT-737 leads to liver deterioration in Mcl-1 knockout
mice, inhibition of Mcl-1 should be done in a tumor specific
manner to induce apoptosis and tumor specific growth control
[40]. We have previously shown that Mcl-1 protein levels rapidly is
decreased in cancer cells when targeted with several of our
Pseudomonas Exotoxin A based immunotoxins [7,11], of which
one (the MOC31PE targeting the EpCAM antigen) is currently in
clinical trial phase I/II (www.clinicaltrials.gov, assessed July 20,
2011). Furthermore, ABT-263/Navitoclax, the oral form of ABT-
737, is currently in phase I and phase II clinical trials (www.
clincaltrials.gov, assessed July 20, 2011). From a clinical perspec-
tive, 9.2.27PE+ABT-263 is therefore an interesting treatment
combination for further investigations. Importantly, administra-
tion of 9.2.27PE+ABT-737 caused growth delay effect in Melmet-
5 xenograft tumors, implying that this particular drug combination
show the ability to kill melanoma cells in vivo. However, as only
tumor growth delay was obtained, treatment of solid melanoma
tumors might prove to be challenging. Immunotoxins and ABT-
737 as single agents have, nevertheless, been shown to be effective
in hematological tumors, where in fact one immunoconjugate
consisting of an IL-2 fused to a modified Diphteria toxin (OntakH)
is approved by the Food and Drug Administration is an option for
patient with cutaneous T-cell lymphoma. To circumvent the
challenges related to treatment of solid metastatic melanoma
tumors, targeting circulating melanoma cells or minimal residual
disease which is present in patients treated with e.g. the new BRAF
or MEK inhibitors (as these patients do relapse after some time),
could be a viable option. As melanoma is a diverse disease, and the
combination treatment with 9.2.27PE+ABT-737 was able to
efficiently cause cell death in several melanoma cell lines tested in
vitro, this approach could reach a broader patient group, not
limited by specific mutations.
Taken together, the combination of 9.2.27PE and the ABT-737
caused synergistic cell death in a panel of melanoma cells, and the
cell death observed was associated with apoptosis involving the
intrinsic apoptosis pathway. ER stress caused by ABT-737, and
enhanced Ca
2+ release caused by ABT-737 as a single agent or the
9.2.27PE+ABT-737 combination treatment, likely contributed to
the cell cytotoxicity and the synergistic anti-melanoma activity.
Importantly, cytostatic effect was obtained in a melanoma
xenograft model, indicating that this combination is effective in
vivo. Whether melanoma cells in vivo will recruit additional survival
mechanisms after treatment with the oral form of ABT-737, the
ABT-263, resulting in resistance to the drug, remains to be
investigated. Lymphoma cells in vitro acquired resistance after long-
term exposure ABT-737 due to up-regulation of Mcl-1 and A1
[41]. We do, however, know that long term exposure of low doses
of 9.2.27PE causes cell cytotoxicity to all melanoma cells in vitro,
due to the general inhibition of protein synthesis leading to cell
death (data not published). Generation of immunotoxin-resistant
cells is therefore not likely to occur.
Supporting Information
Figure S1 The effect of A-793844 on cell viability in melanoma
cells. FEMX and MelRM cells were treated with the enantiomer
A-793844 (the negative control of ABT-737) for the indicated time
points. No significant decrease in cell viability was observed. The
data represents the mean 6 SD.
(TIF)
Figure S2 Both 9.2.27PE and ABT-737 causes active caspase-3
in melanoma cells. FEMX and Melmet-5 cells were treated with
9.2.27PE and ABT-737 as indicated. Active caspase-3 was
measured using the Caspase-Glo 3/7 from Promega. Caspase-3
activation could be inhibited by 45 min pre-incubation with the
caspase-3 inhibitor Z-DEVD-FMK. Staurosporine (STS) was used
as a positive control for caspase-3 activation, and CHX was used
as a negative control.
(TIF)
Figure S3 Calcium release caused by 9.2.27PE6ABT-737 in
melanoma cells. MelRM, MelRMshCtr and MelRMshMcl-1 were
subjected to 9.2.27PE (100 ng/ml)+ABT-737 (10 mM). [Ca
2+]i
levels, and cell viability was measured after 24 h. Knockdown of
Mcl-1 using shRNA enhanced the calcium release and decreased
cell viability caused by ABT-737, an effect which could not be
enhanced by 9.2.27PE. The data shown are the mean 6 SD.
p9=passage 9, the highest passage used for this experiment.
(TIF)
Figure S4 Body weight of nude mice treated with
9.2.27PE6ABT-737. Nude mice were treated with ABT-737
(100 mg/kg) day 1–5 and 15–19 and 9.2.27PE (31.25 mg/kg) on
day 1 and 15 (left panel) or ABT-737 (50 mg/kg) day 1–5 and 15–
19 and 9.2.27PE (31.25 mg/kg) on day 1 and 15 (right panel).
Body weight was measured throughout the experiment.
(TIF)
Table S1 9.2.27PE in combination with ABT-737 causes
synergistic cell cytotoxicity in melanoma cells. Fractional inhibi-
tion=fraction decreased cell viability after treatment, control cells
were set to ‘‘1’’, CI=combination index. CI values below 0.9
indicate synergistic effect. ND=not done.
(DOC)
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